Genomic profiling has identified a subset of metabolic genes that are altered by 1,25-dihydroxyvitamin D (1,25D) in breast cells, including GLUL, the gene that encodes glutamine synthetase (GS). In this study, we explored the relevance of vitamin D modulation of GLUL and other metabolic genes in the context of glutamine utilization and dependence. We show that exposure of breast epithelial cells to glutamine deprivation or a GS inhibitor reduced growth and these effects were exacerbated by cotreatment with 1,25D. 1,25D downregulation of GLUL was sufficient to reduce abundance and activity of GS. Flow cytometry demonstrated that glutamine deprivation induced S phase arrest, likely due to reduced availability of glutamine for DNA synthesis. In contrast, 1,25D induced G 0 /G 1 arrest, indicating that its effects are not solely due to reduced glutamine synthesis. Indeed, 1,25D also reduced expression of GLS1 and GLS2 genes, which code for glutaminases that shunt glutamine into the tricarboxylic acid (TCA) cycle. Consistent with reduced entry of glutamine into the TCA cycle, 1,25D inhibited glutamine oxidation and the metabolic response to exogenous glutamine as analyzed by Seahorse Bioscience extracellular flux assays. Effects of 1,25D on GLUL/GS expression and glutamine oxidation were retained in human mammary epithelial (HME) cells that express SV-40 (HME-LT cells) but not in those that express SV-40 and oncogenic H-Ras (HME-PR cells). Furthermore, HME-PR cells exhibited glutamine independence and expressed constitutively high levels of GLUL/ GS, which were unaffected by 1,25D. Collectively, these data suggest that 1,25D alters glutamine availability, dependence, and metabolism in nontransformed and preneoplastic mammary epithelial cells in association with cell cycle arrest. (Endocrinology 158: 4174-4188, 2017) V itamin D has been identified as a cancer preventive nutrient in preclinical studies (1, 2), and epidemiological studies continue to support its protective role at the population level (3). Vitamin D, whether ingested or synthesized endogenously, gives rise to the systemic hormone 1,25-dihydroxyvitamin D (1,25D), which activates the vitamin D receptor (VDR) to regulate gene expression. The VDR is expressed in mammary epithelial cells and retained in many breast cancers, and studies from VDR knockout mice confirm that the VDR in tumor cells mediates antiproliferative and proapoptotic effects (4-6). Although many VDR targets have been identified through genomic profiling of cells derived from both normal and cancerous tissue, the specific genes and pathways that mediate its cancer preventive effects remain undefined. Our previous studies (7) focused on immortalized normal human mammary epithelial (HME) cell lines, which we demonstrated express VDR and CYP27B1, the enzyme that synthesizes 1,25D from serum-derived 25-hydroxyvitamin D (25D). We also Abbreviations: 1,25D, 1,25-dihydroxyvitamin D; 25D, 25-hydroxyvitamin D; ANOVA, analysis of variance; BPTES, bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide; ECAR, extracellular acidification rate(s); GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GLS, glutaminase; GPNA, L-g-glutamyl-p-nitroanilide; GS, glutamine synthase; HME, human mammary epithelial; HME-LT cell, human mammary epithelial cell that expresses SV-40; HME-PR cell, human mammary epithelial cell that expresses SV-40 and oncogenic H-Ras; L-MS, L-methionine sulfoximine; M171, media 171; mRNA, messenger RNA; OCR, oxygen consumption rate(s); PBS, phosphate-buffered saline; PCR, polymerase chain reaction; SLC1A5, sodium-dependent neutral amino acid transporter type 2; TCA, tricarboxylic acid; VDR, vitamin D receptor.
V itamin D has been identified as a cancer preventive nutrient in preclinical studies (1, 2) , and epidemiological studies continue to support its protective role at the population level (3) . Vitamin D, whether ingested or synthesized endogenously, gives rise to the systemic hormone 1,25-dihydroxyvitamin D (1,25D), which activates the vitamin D receptor (VDR) to regulate gene expression. The VDR is expressed in mammary epithelial cells and retained in many breast cancers, and studies from VDR knockout mice confirm that the VDR in tumor cells mediates antiproliferative and proapoptotic effects (4) (5) (6) . Although many VDR targets have been identified through genomic profiling of cells derived from both normal and cancerous tissue, the specific genes and pathways that mediate its cancer preventive effects remain undefined. Our previous studies (7) focused on immortalized normal human mammary epithelial (HME) cell lines, which we demonstrated express VDR and CYP27B1, the enzyme that synthesizes 1,25D from serum-derived 25-hydroxyvitamin D (25D). We also showed progressive loss of VDR and CYP27B1 expression in HME cells transformed with SV-40 and/or oncogenic H-Ras, changes that led to insensitivity to the growth inhibitory effects of 1,25D and 25D (8) . Using this model, we identified several metabolic genes and pathways regulated by 1,25D in HME cells that became disrupted in transformed variants, including those implicated in glutamine utilization (9) (10) (11) . Alterations in glutamine utilization are particularly prevalent in breast cancer, and several enzymes in glutamine metabolism, including glutamine synthase (GS) and the glutaminases (GLS and GLS2), have emerged as relevant therapeutic targets (12) . Glutamine serves as a critical source of glutamate, which can enter the tricarboxylic acid (TCA) cycle for energy production (13) , essential lipids for membrane synthesis and signaling (14) , and nitrogen for nucleotide synthesis (15) . In the mammary gland, glutamine is synthesized from branched-chain amino acids and secreted at high concentrations into milk (16, 17) . GLUL, the gene encoding for GS, was markedly downregulated by 1,25D in immortalized HME cell lines (9, 18) . GS is frequently upregulated in pancreatic, liver, prostate, and breast cancers, where it promotes proliferation and survival during glutamine deprivation (19) (20) (21) (22) (23) . Conversely, reduction in GS activity is associated with inhibition of cancer cell proliferation and tumor growth (23) and induction of differentiation in mesenchymal stem cells (24) . Collectively, these data suggested that downregulation of GLUL and glutamine metabolism by 1,25D could contribute to its antiproliferative effects in mammary epithelial cells.
Targeting GS is somewhat complicated by the heterogeneity in glutamine dependence that has been reported in breast cells and tumors. This heterogeneity is related to the cell of origin (basal vs luminal epithelial cells) as well as the underlying mutations that drive tumorigenesis. Basal epithelial cells are characterized by low GS expression and are dependent on extracellular glutamine for proliferation, whereas luminal epithelial cells express abundant GS and are glutamine-independent (25) . Several oncogenic pathways (including MYC, WNT, and MET) drive overexpression of GLUL and other glutamine metabolic genes (23, 26) , and breast cancer cells with high activity of these pathways tend to exhibit glutamine dependence. The tumor suppressor p53 regulates genes involved in glycolysis and the TCA cycle (27, 28) , and thus tumors with mutant p53 also exhibit deregulated metabolism. Despite the emerging role of glutamine and GS in breast cancer metabolism, few negative regulators of GLUL expression have been identified. The current studies were designed to assess the relevance of 1,25D regulation of GLUL expression in the context of overall glutamine metabolism in mammary epithelial cells. We previously demonstrated (18) that 1,25D decreased GLUL gene expression in two independently derived immortalized breast epithelial cell lines (hTERT-HME1 and HME) but not in nontumorigenic MCF10A cells or in MCF7, DCIS.com, or Hs578T breast cancer cell lines. Therefore, we also investigated how transformation per se alters glutamine metabolism and the response to 1,25D in the HME model of progression.
Using western blotting, cell density assays, enzyme activity assays, cell cycle analysis, cell viability assays, and extracellular flux analysis, we determined that 1,25D suppresses GLUL/GS and other genes involved in glutamine utilization, reduces glutamine oxidation, and increases the dependence of mammary epithelial cells on exogenous glutamine. Importantly, these effects of 1,25D are maintained in the absence of functional p53 but deregulated in the presence of oncogenic H-Ras. Thus, these studies report novel data linking 1,25D and glutamine metabolism in breast epithelial cells that are consistent with the anticancer effects of vitamin D.
Materials and Methods

Cell culture
HTERT-HME1 cells were obtained from Clontech Laboratories (Mountain View, CA; originally marketed as the Infinity human mammary epithelial cell line, now available from the American Type Culture Collection, Manassas, VA). HME cells, HME cells that express SV-40 (HME-LT cells), and HME cells that express SV-40 and oncogenic H-Ras (HME-PR cells) were obtained from Dr. Robert Weinberg who developed this cellular model of mammary epithelial transformation (29) . As similar results were obtained with hTERT-HME1 and HME cells (both derived from normal human mammary epithelial cells and immortalized with telomerase); representative data from one cell line are shown. However, all data presented for the transformed variants are compared with the parental HME cell line. Cells were cultured in serum-free media 171 (M171) with mammary epithelial growth supplements (Life Technologies, Grand Island, NY), maintained in a 37°C/5% CO 2 incubator and passaged every 3 to 4 days. For experiments requiring varying glutamine concentrations, cells were plated in M171 media for 24 hours and switched to a custom glutaminefree mammary epithelial cell growth medium of the same composition as M171 including supplements (PromoCell, Heidelberg, DE).
Gene expression analysis
GLUL expression was measured by quantitative polymerase chain reaction (PCR) after treatment with 1,25D (SigmaAldrich, St. Louis, MO) or 25D (Sigma-Aldrich). One million cells were plated in M171 media in triplicate 100-mm dishes and allowed to attach. Cells were treated with 1,25D or 25D (100 nM) or ethanol vehicle for 24 hours (or as indicated for time course experiments), followed by RNA isolation using the Qiagen RNeasy kit (Qiagen, Valencia, CA). RNA concentration and purity was analyzed on a NanoDrop 1000 spectrophotometer. Complementary DNA was generated using TaqMan reverse transcription reagents (Life Technologies), and samples were analyzed in duplicate using SYBR Green PCR master mix (ABgene/Thermo Scientific, Pittsburgh, PA) on an ABI Prism 7900HT sequence detection system (Applied Biosystems, Foster City, CA). Primer sequences were obtained from Origene (Rockville, MD) and primers were ordered from Integrated DNA Technologies (Coralville, IA) (Supplemental Table 1 ). Data were calculated using the DDCt method and normalized against 18S. Statistical analysis was conducted with GraphPad Prism software (GraphPad Software, La Jolla, CA) using a one-tailed, unpaired Student t test (a P value of ,0.05 was considered significant, indicated by an asterisk). When multiple time points were compared, data were expressed relative to values obtained for vehicle-treated cells at the earliest time point.
Western blotting
One million cells in 100-mm dishes in M171 media were allowed to attach for 24 hours. Cells were then treated with 100 nM 1,25D or ethanol vehicle in PromoCell custom media with 0 or 2 mM glutamine. After 48 hours of treatment, wholecell lysates were collected and sonicated in 23 Laemmli buffer, and protein concentrations were measured using Pierce BCA protein assays (Thermo Scientific, Rockford, IL). Samples containing 50 mg of protein were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, transferred to polyvinylidene difluoride membranes using semidry transfer, blocked for 1 hour in 5% skim milk/phosphate-buffered saline (PBS), and incubated at 4°C overnight with primary anti-GS antibody (Supplemental Table 2 ) (Sigma-Aldrich) diluted 1:15,000 in 5% skim milk/PBS/0.1% Tween 20. Blots were then incubated for 1 hour with an anti-rabbit ECL horseradish peroxidase-linked secondary antibody (GE Healthcare, Buckinghamshire, UK) diluted 1:5000 in 5% skim milk/PBS/0.1% Tween 20. Pierce ECL2 western blotting substrate (Thermo Scientific, Waltham, MA) was used for imaging of blots on the Storm 860 molecular imaging system (GE Healthcare, Pittsburgh, PA). After imaging, blots were stripped with acetonitrile and reprobed with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primary antibody (AbD Serotec, Raleigh, NC) diluted 1:16,000, followed by incubation with an anti-mouse ECL horseradish peroxidase-linked secondary antibody (GE Healthcare) diluted 1:5,000. Using ImageQuant software, values for GS volume were divided by GAPDH values after background correction. Statistical analysis was conducted for three biological replicates with GraphPad Prism software (GraphPad Software) using one-way analysis of variance (ANOVA) with a Tukey post hoc test (different letters indicate significance, defined as a P value of ,0.05).
Glutamine synthetase activity assay
One million hTERT-HME1 cells were plated in 100-mm dishes in M171 media and, after attachment, treated with 100 nM 1,25D or vehicle for 24 hours. Cells collected and lysed in imidazole buffer were used to measure GS activity as conversion of b-reduced nicotinamide adenine dinucleotide to b-oxidized nicotinamide adenine dinucleotide as described in Sigma-Aldrich technical bulletin "Enzymatic assay of glutamine synthetase" (EC 6.3.1.2) (Sigma-Aldrich). The linear reaction slopes were used to calculate enzyme activity, and activity was expressed per 10 6 cells. Statistical analysis was conducted for three biological replicates with GraphPad Prism software (GraphPad Software) using a one-tailed, unpaired Student t test (a P value of ,0.05 was considered significant, indicated by an asterisk).
Cell density, counts, viability, and cytometric assays Density assays were performed in cells plated in M171 media at 10,000 cells per well in 24-well plates. After attachment, media were switched to PromoCell custom media containing 0 to 4 mM glutamine and 100 nM 1,25D, 100 nM 25D, 1.25 to 5 mM L-methionine sulfoximine (Sigma-Aldrich), or vehicle. After 96 hours (or indicated time point for time course experiments), plates were fixed with 1% glutaraldehyde and stained with 0.1% crystal violet. Stain was resuspended in 0.2% Triton X-100, and absorbance was read at 590 nm on a Victor3 multilabel plate reader (PerkinElmer, Waltham, MA). Statistical analysis was conducted with GraphPad Prism software (GraphPad Software) calculating one-way ANOVA with a Tukey post hoc test (different letters indicate significance, defined as a P value of ,0.05) or a one-tailed, unpaired Student t test (a P value of ,0.05 was considered significant, indicated by an asterisk).
For cell counts, hTERT-HME1 cells were plated in triplicate at a density of 100,000 cells per well of a six-well plate in M171 media. After attachment, cells were switched to PromoCell custom media containing 0 or 2 mM glutamine and 100 nM 1,25D or vehicle for 72 hours. Following treatment, cells were trypsinized, pelleted in spent media, and resuspended in 1% fetal bovine serum/PBS. Muse VIA reagent (EMD Millipore, Billerica, MA) was added and samples were analyzed on the count and viability program of the Muse cell analyzer (EMD Millipore). Statistical analysis was conducted with GraphPad Prism software (GraphPad Software) using one-way ANOVA with a Tukey post hoc test (different letters indicate significance, defined as a P value of ,0.05).
For cell cycle analysis, hTERT-HME1 cells were plated in triplicate at a density of 100,000 cells per well of a six-well plate in M171 media. After attachment, cells were switched to PromoCell custom media containing 0 or 2 mM glutamine and 100 nM 1,25D or vehicle for 72 hours. Cells were trypsinized, pelleted in spent media, and fixed in 90% EtOH overnight at 220°C after treatment. Cells were washed with 0.2% bovine serum albumin/PBS, pelleted, and resuspended in Muse cell cycle reagent (EMD Millipore). Samples were analyzed on the cell cycle program of the Muse cell analyzer (EMD Millipore) after a 30-minute incubation. Statistical analysis was conducted with GraphPad Prism software (GraphPad Software) using oneway ANOVA with a Tukey post hoc test (different letters indicate significance, defined as a P value of ,0.05).
Seahorse Bioscience XFp extracellular flux analysis HME and HME-LT cells were plated at a density of 25,000 cells per well and HME-PR cells at a density of 20,000 cells per well in M171 media in Seahorse Bioscience (North Billerica, MA) XFp tissue culture microplates. After attachment, cells were treated for 48 hours with 100 nM 1,25D or vehicle. For basal oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) measured in the presence and absence of glucose, cells were switched to buffer-free XF assay media (Seahorse Bioscience) containing 2 mM glutamine, 1 mM pyruvate, and 0 or 10 mM glucose 1 hour prior to assay. The XFp extracellular flux analyzer (Seahorse Bioscience) measured OCR and ECAR over time and data were calculated by normalizing to DNA concentration. For glutamine oxidation studies, media were switched to buffer-free XF assay medium supplemented with 10 mM glucose, 1 mM sodium pyruvate, and 2 mM glutamine for 1 hour prior to run. 30 mM bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (Sigma-Aldrich), 40 mM etomoxir (SigmaAldrich), and 20 mM UK5099 (Sigma-Aldrich) were added to drug ports in the sensor plate for timed injections as per the XF Mito Fuel Flex Test protocol. OCR was measured and data were calculated by dividing OCR values after inhibition of glutamine oxidation by total glucose, glutamine, and fatty acid oxidation normalized to DNA concentration. For glutamine or glucose injection studies, XF assay medium was prepared as above without glutamine or glucose, and 2 mM glutamine or 10 mM glucose was injected during the run. OCR and ECAR were measured before and after each injection. Data were calculated by subtracting OCR/ECAR baseline readings from readings measured after injection and normalizing to DNA concentration. Metabolic flux data represent the mean of three independent biological replicates. Statistical analysis by a onetailed, paired Student t test (a P value of ,0.05 was considered significant, indicated by an asterisk) or repeated measures ANOVA with a Tukey post hoc test as appropriate was performed with GraphPad Prism software (GraphPad Software).
Results
Effect of vitamin D signaling on GLUL expression and GS activity in hTERT-HME1 cells
We previously reported significant changes in metabolic gene expression in several nontumorigenic breast epithelial cell lines, including hTERT-HME1 cells, exposed to 100 nM 1,25D for 24 hours (9). One of the 1,25D downregulated genes in these model systems was GLUL, which codes for GS and is often upregulated in rapidly proliferating cells. We further assessed the relevance of 1,25D regulation of GLUL and GS in these human mammary epithelial cells and in derivative cell lines expressing SV-40 and oncogenic H-Ras. The kinetics of GLUL gene expression was first examined in hTERT-HME1 cells exposed to 100 nM 1,25D or vehicle for up to 12 hours. GLUL expression was stable in vehicle-treated cells but was significantly reduced within 8 hours of 1,25D treatment and remained downregulated at 12 ( Fig. 1A ) and 24 hours (12) . GLUL expression was also decreased (;50%) after 24-hour treatment with 100 nM 25D, the circulating form of vitamin D (Supplemental Fig. 1 ). This observation is consistent with previous data that demonstrated CYP27B1 expression, 1,25D synthesis, and 25D-mediated growth inhibition in hTERT-HME1 cells (7) and suggests that GLUL regulation by 1,25D is likely to be physiologically relevant.
Because GLUL codes for GS, an enzyme that generates glutamine, we hypothesized that downregulation of GLUL by 1,25D could induce intracellular glutamine depletion if GS abundance was sufficiently reduced. We therefore assessed the effect of 1,25D on expression and activity of GS. Cells were grown in the presence and absence of glutamine because previous studies have suggested that GS abundance is increased under conditions of glutamine starvation (25, 30) . For these experiments, hTERT-HME1 cells were plated in media containing the standard glutamine concentration (2 mM) and switched after 24 hours to media containing 2 mM or 0 mM glutamine, with or without 100 nM 1,25D. Western blots were conducted 48 hours after media switch. In glutaminecontaining media, GS was detected as a band at 42 kDa corresponding to the full-length protein (Fig. 1B) . In contrast to reports in breast cancer cells (25) , glutamine deprivation did not enhance GS expression in these nontransformed hTERT-HME1 cells. Consistent with the GLUL messenger RNA (mRNA) expression data, a marked decrease (60%) in GS expression was observed in lysates from 1,25D-treated hTERT-HME1 cells regardless of media glutamine concentration (Fig. 1C) . To determine whether the 1,25D-mediated downregulation of GS protein was sufficient to decrease enzyme activity, GS activity was assayed in lysates from cells treated with 1,25D. GS activity was detected in hTERT-HME1 cells and was reduced by nearly 50% within 24 hours of treatment with 1,25D (Fig. 1D) .
Effects of 1,25D and glutamine on hTERT-HME1 cell growth, viability, and cell cycle kinetics
In many cell types and tumors, the conversion of glutamate to glutamine by GS is essential for cell growth and survival upon glutamine deprivation (23, 30) . We thus hypothesized that reduced GS activity in 1,25D-treated cells would inhibit hTERT-HME1 cell growth and limit adaptation to glutamine deprivation. To test this hypothesis, we altered media glutamine concentrations and examined growth of hTERT-HME1 cells in the presence and absence of 1,25D during a 4-day time course (Fig. 2A) . Growth of cultures in media containing 2 mM glutamine (standard media concentration) was not enhanced by supplemental glutamine (4 mM). Upon glutamine deprivation, cell density continued to increase over time but at a slower rate than that of cells in media containing 2 mM or 4 mM glutamine. In contrast, density of cultures treated with 1,25D increased for the first 48 hours and then plateaued, indicating growth arrest. This pattern was observed at all media glutamine concentrations, and density was lowest in 1,25D-treated cells subjected to glutamine deprivation. Dose response experiments with lower concentrations of glutamine demonstrated that maximal growth could be achieved in media with 0.5 mM glutamine, and that although the density of 1,25D-treated cultures was higher in media containing 0.5 mM glutamine than those without glutamine, density was always less in 1,25D-exposed cultures compared with that of control cultures (Fig. 2B) . Similar results were observed with 25D treatment, with glutamine enhancing growth of cells incubated in low (25 to 50 nM) but not high (100 nM) concentrations of 25D (Supplemental Fig. 2 ).
Flow cytometry was used to determine the relative effects of glutamine deprivation and 1,25D on cell viability and cell cycle kinetics after 72 hours. Consistent with cell density assays, total cell number was consistently lower after 1,25D treatment irrespective of glutamine concentration, and the lowest total cell counts were observed in cells treated with 1,25D and deprived of glutamine (Fig. 3A) . However, although both glutamine deprivation and 1,25D treatment reduced total cell numbers, neither manipulation alone increased the percentage of dead cells (Fig. 3B) . A significant increase in cell death was only observed in cultures subjected to both glutamine deprivation and 1,25D treatment, suggesting that the reduction of GS activity by 1,25D prevents intracellular generation of glutamine, inducing dependence on extracellular glutamine for survival.
We next examined the effects of 1,25D and glutamine starvation on cell cycle progression. Glutamine starvation for 72 hours resulted in significantly fewer cells in G 0 /G 1 and significantly more cells in S phase (Table 1) , suggesting a reduced ability of cells to complete S phase and enter G 2 /M. In contrast, 1,25D treatment significantly increased the percentage of cells in G 0 /G 1 and decreased the percentage in S and G 2 /M phases indicative of G 0 /G 1 arrest. Therefore, although both 1,25D and glutamine starvation decrease total cell counts, the mechanisms of cell cycle arrest differed, with glutamine deprivation preventing S phase completion (likely due to the requirement of glutamine as a nitrogen donor for nucleotide synthesis) and 1,25D preventing G 0 /G 1 exit at the restriction point (likely through transcriptional regulation of cyclin-dependent kinases and their inhibitors). When cultures were deprived of glutamine and treated with 1,25D, the G 0 /G 1 population was decreased, S phase was unchanged, and the G 2 /M population was increased.
To more specifically explore the requirement of hTERT-HME1 cells for de novo glutamine synthesis, we used a pharmacologic GS inhibitor, L-methionine sulfoximine (L-MS). Cell density assays were performed 96 hours after cells were treated with varying doses of L-MS in glutamine-replete or glutamine-depleted media. Even in the absence of extracellular glutamine, L-MS further reduced hTERT-HME1 cell density in a dosedependent manner (Fig. 4A) , indicating that GS-mediated generation of glutamine is required for optimal growth of hTERT-HME1 cells. Addition of glutamine to the media enhanced the growth of cultures treated with low (#2.5 mM) concentrations of L-MS but was unable to rescue growth of cultures treated with 5 mM L-MS, a concentration that irreversibly inactivates the enzyme (31) . The requirement of hTERT-HME1 cells for exogenous glutamine was further confirmed with 1 mM L-g-glutamyl-p-nitroanilide (GPNA), a specific inhibitor of the glutamine transporter sodium-dependent neutral amino acid transporter type 2 (SLC1A5). SLC1A5 is associated with glutamine independence in cancer cells that is repressed by 1,25D in Ras-transformed MCF10A cells (10) . Consistent with the L-MS data, GPNA treatment markedly reduced hTERT-HME1 cell density in glutamine-containing media (Fig. 4B) . However, 1,25D did not reduce SLC1A5 gene expression (Fig. 4D ) or protein abundance (Fig. 4E) in this model system.
Another critical role of glutamine is to replenish TCA cycle intermediates through its conversion to glutamate, a reaction catalyzed by several distinct mitochondrial glutaminases. The GLS gene codes for kidney-type glutaminase, which has been linked to glutamine independence driven by the MYC oncogene. We used the glutaminase inhibitor BPTES to determine whether blocking intracellular conversion of glutamine to glutamate affects growth of hTERT-HME1 cells. As shown in Fig. 4C , BPTES strongly reduced cell density (even in media containing glutamine), indicating that shunting of intracellular glutamine into glutamate is necessary for optimal cell growth. Interestingly, 1,25D treatment reduced GLS gene expression within 24 hours and protein abundance within 48 hours (Fig. 4D and 4E ). 1,25D also downregulated the GLS2 gene ( Fig. 4D and 4E) , which codes for the liver glutaminase isoform, but did not reduce protein abundance in the time frame studied (48 hours). Collectively, these data demonstrate that 1,25D blocks two major enzymes of glutamine metabolism, GS and GLS, which are required for glutamine flux into macromolecule synthesis and energy production, respectively.
Effect of transformation on glutamine dependence and response to 1,25D
Transformation is often associated with glutamine independence and has also been shown to deregulate vitamin D signaling and CYP27B1 expression/activity (8) . We thus explored whether transformation per se altered mammary epithelial cell glutamine requirements or the metabolic effects of 1,25D. We previously observed repression of GLUL gene expression by 1,25D in telomerase-immortalized HME cells and in a derivative line engineered to express SV-40 (HME-LT cells), but not in cells engineered to express SV-40 and oncogenic H-Ras (HME-PR cells) (9) . We thus examined GS expression, glutamine dependence, and the effects of 1,25D in this model of mammary cell transformation. As shown in Fig. 5 , GS protein abundance was low in HME cells but increased threefold to fivefold in HME-LT and HME-PR cells. Treatment with 1,25D for 48 hours significantly reduced GS expression in HME cells and HME-LT cells but not in HME-PR cells. Based on these data, we hypothesized that HME and HME-LT cells would exhibit glutamine dependence (especially in the presence of 1,25D), whereas HME-PR cells would be relatively insensitive to glutamine deprivation. Indeed, growth of HME and HME-LT cells was reduced in media lacking glutamine or containing 1,25D (Fig. 6 ) or 25D (Supplemental Fig. 3 ), although sensitivity to vitamin D metabolites was lower in HME-LT relative to HME cells. In contrast, neither 1,25D or glutamine deprivation altered the density of HME-PR cultures. As would be predicted if GS reduction contributes to the growth inhibitory effects of 1,25D, exogenous glutamine partially enhanced growth of HME and HME-LT cells (but not HME-PR cells) exposed to 1,25D, but density was not fully restored to that of control cells. These data suggest that reduced expression of GS in 1,25D/25D-treated HME and HME-LT cells promotes glutamine dependence, whereas high-constitutive GS associated with oncogenic H-Ras in HME-PR cells maintains intracellular glutamine and renders cells independent of exogenous glutamine.
Effects of 1,25D on oxidative phosphorylation and glycolysis in HME cells and transformed variants
To further assess the impact of 1,25D and glutamine metabolism in this model of transformation, we measured OCR (a measure of oxidative phosphorylation) and ECAR (a measure of glycolysis) with a Seahorse Bioscience XFp extracellular flux analyzer. As noted above, the reduction in GLS expression in 1,25D-treated HME cells would be predicted to reduce the availability of glutamate, which normally contributes to anaplerosis of the TCA cycle. Indeed, 1,25D-treated HME cells exhibited higher ECAR compared with control cells when assayed in full media containing glucose, glutamine, and pyruvate as fuel sources (Fig. 7, left bars) . When cells were assayed in the absence of glucose to limit glycolysis and force cells to rely on glutamine and pyruvate for energy, control cells significantly increased OCR whereas the response in 1,25D-treated cells was blunted (Fig. 7, right  bars) . However, both control and 1,25D-treated cells exhibited similar reductions in ECAR in the absence of glucose. To further probe changes in response to glucose availability, changes in OCR and ECAR were measured following acute glucose pulse as described (32) . HME cells were incubated for 1 hour in buffer-free media containing glutamine and pyruvate, and OCR and ECAR were measured prior to and following the addition of glucose (10 mM). 1,25D-treated cells exhibited a significantly greater rise in ECAR after glucose injection (Fig. 8A) , suggesting preference for glucose metabolism via glycolysis despite the availability of glutamine. 1,25D Figure 4 . Effects of inhibitors and 1,25D on HME and hTERT-HME1 cell density and expression of glutamine metabolism-associated genes/proteins. After attachment, hTERT-HME1 cells were switched to media containing 0 or 2 mM GLN and (A) 1.25 to 5 mM L-MS for 96 hours. After attachment, HME cells were switched to media containing (B) 1 mM L-g-glutamyl-p-nitroanilide (GPNA) or (C) 1.5 mM Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) or dimethyl sulfoxide vehicle for 96 hours. For (A-C), cells were fixed and stained with crystal violet. Stain was resuspended in Triton X-100 and absorbance was read at 590 nm. (D) Quantitative PCR analysis of GLS, GLS2, and SLC1A5 in 1,25D-treated hTERT-HME1 cells. Cells were treated with 100 nM 1,25D or ethanol vehicle (Con) for 24 hours. RNA was isolated and real-time quantitative PCR was performed. The data were normalized to 18S and expressed relative to control values set to 1. (E) After attachment, HME cells were treated with 100 nM 1,25D or ethanol vehicle (Con) for 48 hours. Whole-cell lysates were analyzed by Western blotting with antibodies against GLS, GLS2, SLC1A5, or GAPDH as loading control. Blot represents one of three biological replicates and normalized densitometry of replicate blots was calculated. For (A-E), lines and bars represent the mean of three independent biological replicates 6 standard deviation. *P , 0.05 as measured by one-tailed, unpaired Student t test.
treatment did not alter the OCR response to glucose injection (Fig. 8B ), again supporting a preferential reliance on glycolysis. We next used the XF Mito Fuel Flex assay to specifically assess how 1,25D affects glutamine handling relative to that of glucose and pyruvate in HME, HME-LT, and HME-PR cells. Briefly, vehicle-and 1,25D-treated cells were incubated in media containing glucose, glutamine, and pyruvate, and OCR was monitored sequentially after injection of BPTES (GLS inhibitor), etomoxir (inhibitor of long-chain fatty acid oxidation), and UK5099 (inhibitor of glucose oxidation). Data were calculated by dividing glutamine oxidation by total oxidation of all three fuels and normalized to DNA concentration. As shown in Fig. 9, 1 ,25D treatment significantly reduced glutamine oxidation in HME and HME-LT cells but not in HME-PR cells. Also evident in Fig. 9 is that basal glutamine oxidation was higher in both HME-LT and HME-PR cells compared with nontransformed HME cells. Collectively, these results suggest that reductions in GS and GLS activity in 1,25D-treated HME and HME-LT cells are sufficient to limit glutamine oxidation.
To complement the data on glutamine utilization generated with chemical inhibitors, we measured the response to acute glutamine availability in HME and HME-PR cells (32) . For this assay, cells were incubated for 1 hour in buffer-free media containing only glucose and pyruvate as fuel sources and OCR and ECAR were monitored before and after acute exposure to glutamine (2 mM). Prior to glutamine injection into assay media, 1,25D-treated HME cells exhibited lower OCR and higher ECAR compared with control HME cells (not shown). In contrast, OCR was higher in HME-PR cells compared with HME cells and was unaffected by 1,25D. In response to glutamine injection (Fig. 10) , HME cells exhibited a shift from glucose utilization to glutamine utilization as evidenced by a reduction in ECAR and an increase in OCR (Fig. 10A ). This shift from ECAR to OCR after glutamine injection was markedly blunted in 1,25D-treated cells, suggesting that extracellular glutamine availability per se is not the limiting factor in the impaired OCR response of 1,25D-treated cells. HME-PR cells also responded to glutamine injection with a reduction in ECAR and an increase in OCR, but the effect of 1,25D on this shift in the transformed cells was minimal (Fig. 10B) . The overall lack of effect of 1,25D on glutamine metabolism in HME-PR cells is consistent with the lack of effect of 1,25D on GS, GLS, GLS2, and SLC1A5 expression in these cells (Fig. 5 and data not shown).
To summarize, the metabolic flux assays indicated that 1,25D-treated cells are capable of glycolysis in the presence of exogenous glucose but display impaired oxidative phosphorylation even in the presence of exogenous glutamine. These findings can be attributed to the downregulation of GS and GLS by 1,25D and are consistent with metabolomic data reported by Zhou et al. (10) in MCF10A cells.
In conclusion, these studies have defined the glutamine requirements of hTERT-HME1 cells and its transformed variants and demonstrated that 1,25D alters central metabolism leading to reduced glutamine utilization. As depicted in our model (Fig. 11) , the effects of 1,25D include suppression of GLUL, which reduces de novo glutamine synthesis and limits its availability for nucleotide synthesis, and downregulation of GLS1, which reduces glutaminolysis and limits glutamate availability as fuel for the TCA cycle. Together these actions provide an explanation for the inability of exogenous glutamine to completely overcome the growth-limiting effects of 1,25D. The extent to which the effects of 1,25D on glutamine metabolism contribute to its growth inhibitory actions in mammary cells remains to be dissected in future Figure 5 . Effects of 1,25D on GS expression in an HME transformation series. After attachment, cells were treated with 100 nM 1,25D or ethanol vehicle (Con) for 48 hours. Whole-cell lysates were analyzed by Western blotting with antibodies against GS or GAPDH as loading control. Numbers represent volume of GS band divided by the corresponding GAPDH band followed by normalization to HME control. (A) Blot represents one set of three biological replicates. (B) Normalized densitometry of replicate blots. Bars represent the mean of three independent biological replicates 6 standard deviation. *P , 0.05 as measured by one-tailed, unpaired Student t test.
studies. However, the concurrent loss of VDR signaling and escalation of glutamine requirement upon H-Ras transformation support such a link.
Discussion
These studies demonstrate that 1,25D, the natural ligand for the VDR, regulates genes involved in control of the glutamine-glutamate metabolic hub in nontransformed mammary epithelial cells and that this regulation becomes corrupted during transformation. The metabolic role of glutamine in both normal mammary gland and in breast cancer is well documented, and further studies are necessary to evaluate the importance of its regulation by vitamin D in vivo. The physiological relevance of our findings is supported by the documented expression of the VDR in the mammary gland, which is inversely correlated with proliferation (33) and is dynamically regulated during puberty, pregnancy, lactation, and involution (34, 35) . Effects of vitamin D on intact mammary tissue in culture include abrogation of diet-and hormone-driven proliferation, enhancement of calcium transport, regulation of immune responses, and inhibition of chemical carcinogenesis (36) (37) (38) (39) . RNA sequencing of normal breast tissue revealed 127 genes that were differentially expressed in response to acute 1,25D treatment ex vivo, including those involved in amino acid metabolic pathways. While no studies have yet reported the impact of vitamin D on genomic profiles of breast tissue from healthy women, several do support Figure 6 . Effects of glutamine and 1,25D on cell density in an HME transformation series. After attachment, cells were switched to media containing 0, 2, or 4 mM glutamine (GLN) and 100 nM 1,25D or ethanol vehicle (Con) for 96 hours. Cells were fixed and stained with crystal violet. Stain was resuspended in Triton X-100 and absorbance was read at 590 nm. Bars represent the mean of three independent biological replicates 6 standard deviation. *P , 0.05 compared with 0 mM GLN/ Con absorbance as measured by one-tailed, unpaired Student t test. an impact of vitamin D status on breast biology. For instance, serum 25D correlated with secretion of MCP-1 and TRAIL in breast milk (40, 41) and secretion of TGFb2 and prostaglandin E 2 in nipple aspirate fluid (42) . These data provide precedent that vitamin D exerts physiologically relevant effects on breast function in healthy women. Changes in amino acid metabolism in mammary epithelial cells, as suggested by our data, could contribute to or complement these biological effects of vitamin D in the gland.
The specific functions of glutamine in normal mammary cells have primarily been studied in the context of lactation. Glutamine is present in high concentrations in milk (both as free glutamine and in proteins) and its synthesis in mammary epithelial cells is inhibited by growth hormone but stimulated by cortisol and glucagon (16, 43) . Our data suggest that 1,25D and the VDR also contribute to the regulation of glutamine synthesis in mammary cells via control of GS. 1,25D downregulated GLUL mRNA and GS abundance within 8 hours, suggesting that this gene may be a direct VDR target. This finding is consistent with the identification of a consensus VDR binding site within 210 kb to 5 kb of the gene (44) . Furthermore, the 1,25D precursor, 25D, reduced GLUL expression at concentrations achievable in vivo, confirming CYP27B1 activity in mammary epithelial cells and supporting physiologic relevance of this regulation. In addition to control of glutamine availability, newly recognized roles of GS include control of mTOR signaling and autophagy (45) , which may underlie the effects of vitamin D on mammary gland involution (46) .
Although technically classified as a "nonessential" amino acid, glutamine often becomes limiting in rapidly proliferating cancer cells, and pharmacologic targeting of its metabolism is of major interest in oncology (13, (47) (48) (49) . Induction of GS has long been associated with carcinogenesis and escape from glutamine dependence (50) (51) (52) . These studies initially tested the hypothesis that insufficient glutamine production secondary to decreased GS activity would render 1,25D-treated mammary epithelial cells dependent on glutamine and that exogenous glutamine would restore growth of 1,25D-treated cells. Our data do not fully support this hypothesis because increased extracellular glutamine did not restore growth of cultures treated with high concentrations of 1,25D (although it was effective in rescuing cells incubated with physiological concentrations of 25D). Additionally, cell cycle analysis indicated that glutamine deprivation resulted in S phase arrest whereas 1,25D treatment resulted in G 0 /G 1 arrest. Real-time analysis of metabolic rates indicated that 1,25D-treated cells exhibited impaired oxidative metabolism even in the presence of exogenous glutamine. These results suggested that 1,25D might regulate genes in addition to GLUL that affect glutamine entry into the TCA cycle for oxidation. Further analysis demonstrated that 1,25D suppressed expression of GLS1 and GLS2 and reduced the abundance of KGA, the glutaminase coded for by GLS1. Glutaminases metabolize glutamine to glutamate, which after conversion to a-ketoglutarate enters the TCA cycle. Reduced glutaminase activity provides an explanation for the decreased glutamine oxidation and the failure of exogenous glutamine to restore Figure 9 . 1,25D effects on glutamine (GLN) oxidation in HME transformation series. After attachment, cells were treated with 100 nM 1,25D or ethanol vehicle (Con) for 48 hours. The XFp extracellular flux analyzer measured OCR over time following an initial injection of 3 mM BPTES and a second injection of 4 mM etomoxir and 2 mM UK5099. Data were calculated by dividing OCR values after inhibition of glutamine oxidation by total glucose, glutamine, and fatty acid oxidation and normalized to DNA concentration. Each bar represents the mean of three independent biological replicates 6 standard deviation. *P , 0.05 as measured by onetailed, paired Student t test. growth in the presence of 1,25D. Our data in nontransformed mammary epithelial cells expand previous reports of 1,25D actions on glutamine metabolism in MCF10A mammary epithelial cells (10) yet also highlight some cell-specific responses. In both cell models, 1,25D blocks glutamine metabolism, but this was attributed to repression of SLC1A5 and inhibition of glutamine uptake in MCF10A cells in contrast to hTERT-HME1 cells in which 1,25D repressed GLUL and GLS1 but not SLC1A5. Given the interest in targeting glutamine metabolism in oncology, we examined whether transformation altered glutamine dependency in the presence or absence of 1,25D. Using an in vitro model of mammary epithelial cell transformation (29), we previously showed that many effects of 1,25D are abrogated upon transformation (9) . The studies reported here monitored changes in oxidative phosphorylation and glycolysis in real time and demonstrated that introduction of SV-40 (which disrupts p53 and other tumor suppressive pathways) did not abrogate the effects of 1,25D on GLUL, GS, or glutamine oxidation. In both HME cells and a derivative expressing SV-40 (HME-LT cells), 1,25D suppressed GLUL expression (9) and GS abundance while blunting the oxidative response to acute glutamine exposure. In contrast, 1,25D did not alter GLUL, GS, or glutamine oxidation in the HME-PR cells harboring oncogenic H-Ras. Furthermore, HME-PR cells exhibited elevated basal OCR and rapid growth rates in the presence or absence of 1,25D regardless of exogenous glutamine concentration. From these data, we conclude that normal (HME) and preneoplastic (HME-LT) cells are competent for vitamin D control of glutamine metabolism whereas transformed cells (HME-PR) exhibit markedly high GLUL expression, glutamine-independent growth, and generalized resistance to 1,25D.
In addition to the altered regulation of GLUL expression in this cellular model of transformation, oncogenes and loss of tumor suppressors have been shown to exert profound effects on VDR signaling through multiple mechanisms. H-Ras-mediated phosphorylation of the VDR heterodimer partner retinoid X receptor has been shown to alter 1,25D sensitivity (53) . Other studies have indicated that H-Ras destabilizes VDR mRNA and abrogates VDR transcriptional activity (54) (55) (56) . VDR interacts with the tumor suppressor p53 at common target promoters, including p21 (57) , and is also transcriptionally induced by p53 (58) . In HME-PR cells, the combined deregulation of p53 and gain of H-Ras signaling likely alters VDR function sufficiently to result in general desensitization to 1,25D. Note, however, that not all H-Ras-transformed cells are insensitive to 1,25D, as 1,25D exerts significant effects on glutamine metabolism in MCF10A-ras cells (10) . Given the complexity of VDR targets, further studies are required to determine whether disruptions in Figure 10 . 1,25D effects on OCR and ECAR in (A) HME and (B) HME-PR cells. After attachment, cells were treated with 100 nM 1,25D or ethanol vehicle (Con) for 48 hours. The XFp extracellular flux analyzer measured OCR and ECAR over time before and after an injection of glutamine (2 mM). Data were calculated by subtracting baseline OCR/ECAR values from values after injection and normalized to DNA concentration. Each bar represents the mean of three independent biological replicates 6 standard deviation. *P , 0.05 as measured by one-tailed, paired Student t test.
VDR signaling are necessary or sufficient to drive the changes in glutamine metabolism observed in HME-PR cells (elevated GS, high basal OCR, and glutamine independence).
In summary, these studies have demonstrated that optimal growth of hTERT-HME1 cells, an immortalized but nontumorigenic breast epithelial cell line, requires glutamine for nucleotide synthesis and oxidative phosphorylation. Additionally, we report that 1,25D represses GLUL and GLS1, enzymes critical for glutamine synthesis and metabolism. Given the dynamic regulation of VDR expression in the mammary gland, our data suggest that vitamin D may work in conjunction with other signals, such as cortisol and growth hormone, to control glutamine synthesis during the reproductive cycle. Additionally, the observation that mammary cells engineered to express H-Ras concurrently become unresponsive to 1,25D and exhibit glutamine independence implies a causal link between vitamin D and glutamine metabolism. Future studies to examine this link, particularly in the context of other mediators of the cancer-associated metabolic switch, such as MYC and hypoxia, are warranted. Figure 11 . Model for impact of vitamin D signaling on glutamine metabolism. Glutamine uptake requires membrane transporters such as SLC1A5. Once internalized, glutamine can be shunted toward macromolecule synthesis (nucleotide synthesis shown) or converted to glutamate by mitochondrial GLS. The major fate of glutamate is conversion to a-ketoglutarate, which is metabolized in the TCA cycle. Alternatively, glutamate can be reconverted to glutamine by GS. GPNA, L-MS, and BPTES inhibit proteins involved in glutamine metabolism as shown. 1,25D downregulates GS and GLS in association with growth arrest. GLN, glutamine; GLU, glutamate.
